Clinical Trials Logo

Lymphoblastic Leukemia, Acute clinical trials

View clinical trials related to Lymphoblastic Leukemia, Acute.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00995137 Completed - Clinical trials for Lymphoblastic Leukemia, Acute

Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia

Start date: October 2009
Phase: Phase 1
Study type: Interventional

This study will determine the maximum tolerated dose of genetically modified natural killer (NK) cells in research participants with relapsed or refractory B-lineage acute lymphoblastic leukemia (ALL).

NCT ID: NCT00391989 Completed - Clinical trials for Lymphoblastic Leukemia, Acute

Treatment of Adult Ph+ LAL With BMS-354825

Start date: September 2006
Phase: Phase 2
Study type: Interventional

The primary objective of the trial is to estimate the activity of BMS-354825 (Dasatinib) in de novo adult Ph+ ALL patients in terms of hematological complete remission (HCR) rate.

NCT ID: NCT00137111 Completed - Clinical trials for Lymphoblastic Leukemia, Acute

Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Start date: July 8, 2000
Phase: Phase 3
Study type: Interventional

The primary objective is to estimate the overall event-free survival of children at least one year of age at diagnosis who are treated with risk-directed therapy and to monitor the molecular remission induction rate.

NCT ID: NCT00114348 Completed - Clinical trials for Lymphoma, Non-Hodgkin

ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia

Start date: August 2003
Phase: Phase 4
Study type: Interventional

The protocol ALL-REZ BFM 2002 aims at the optimization of treatment for children with relapsed acute lymphoblastic leukemia. The primary objective of study ALL-REZ BFM 2002 is the randomized comparison of a lower dosed and less intensive, but continuous consolidation therapy with conventional therapy administered in treatment blocks. Outcome measures are the reduction of minimal residual disease (MRD), event-free and overall survival, and the toxicity associated with each treatment strategy.